C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
C4 Therapeutics (Nasdaq: CCCC) announced upcoming data presentation from its Phase 1 trial of cemsidomide in multiple myeloma at the International Myeloma Society Annual Meeting on September 20, 2025. The company has completed enrollment and dose escalation for the trial, which combines cemsidomide with dexamethasone.
The presentation will feature data from all safety and efficacy evaluable multiple myeloma patients across all dose levels. Initial results indicate a well-tolerated safety profile and compelling response rates. Dr. Binod Dhakal from the Medical College of Wisconsin will present the findings at 11:10 am ET in Toronto. C4T will host an investor webcast at 3 pm ET the same day to discuss the data and outline future clinical development plans.
C4 Therapeutics (Nasdaq: CCCC) ha annunciato che presenterà i dati del suo trial di Fase 1 su cemsidomide nel mieloma multiplo durante l'International Myeloma Society Annual Meeting il 20 settembre 2025. Lo studio, che combina cemsidomide con desametasone, ha completato l'arruolamento e l'escalation delle dosi.
La presentazione includerà i dati provenienti da tutti i pazienti valutabili per sicurezza ed efficacia in ogni livello di dose. I risultati preliminari mostrano un profilo di sicurezza ben tollerato e tassi di risposta promettenti. Il dott. Binod Dhakal del Medical College of Wisconsin illustrerà i risultati alle 11:10 ET a Toronto. C4T terrà inoltre una webcast per gli investitori alle 15:00 ET lo stesso giorno per commentare i dati e illustrare i piani di sviluppo clinico futuri.
C4 Therapeutics (Nasdaq: CCCC) anunció que presentará datos de su ensayo de Fase 1 de cemsidomide en mieloma múltiple en la Reunión Anual de la International Myeloma Society el 20 de septiembre de 2025. El estudio, que combina cemsidomide con dexametasona, ha completado la inscripción y la escalada de dosis.
La presentación incluirá datos de todos los pacientes evaluables por seguridad y eficacia en todos los niveles de dosis. Los resultados iniciales indican un perfil de seguridad bien tolerado y tasas de respuesta convincentes. El Dr. Binod Dhakal del Medical College of Wisconsin expondrá los hallazgos a las 11:10 ET en Toronto. C4T ofrecerá además una webcast para inversores a las 3:00 pm ET ese mismo día para discutir los datos y detallar los planes de desarrollo clínico futuros.
C4 Therapeutics (Nasdaq: CCCC)는 cemsidomide에 대한 다발성 골수종 1상 시험 결과를 2025년 9월 20일 International Myeloma Society 연례회의에서 발표할 예정이라고 밝혔습니다. 데사메타손과 병용하는 해당 임상은 등록과 용량 증량을 완료했습니다.
발표에는 모든 용량군에서 안전성 및 유효성 평가가 가능한 환자 전체의 데이터가 포함됩니다. 초기 결과는 양호한 내약성의 안전성 프로파일과 유의미한 반응률을 시사합니다. 위스콘신 의과대학의 비노드 다칼 박사가 토론토에서 현지시간 오전 11시 10분(ET)에 결과를 발표합니다. C4T는 동일한 날 오후 3시(ET)에 투자자 대상 웹캐스트를 개최해 데이터를 설명하고 향후 임상 개발 계획을 제시할 예정입니다.
C4 Therapeutics (Nasdaq: CCCC) a annoncé la présentation de données issues de son essai de phase 1 sur le cemsidomide dans le myélome multiple lors de la réunion annuelle de l'International Myeloma Society le 20 septembre 2025. L'étude, qui associe le cemsidomide à la dexaméthasone, a terminé le recrutement et l'escalade des doses.
La présentation couvrira les données de tous les patients évaluables pour la sécurité et l'efficacité à tous les niveaux de dose. Les résultats initiaux montrent un profil de sécurité bien toléré et des taux de réponse convaincants. Le Dr Binod Dhakal du Medical College of Wisconsin présentera les résultats à 11h10 ET à Toronto. C4T organisera également le même jour à 15h00 ET un webcast pour les investisseurs afin de commenter les données et d'exposer les plans de développement clinique futurs.
C4 Therapeutics (Nasdaq: CCCC) kündigte an, Daten aus seiner Phase-1-Studie zu cemsidomide beim multiplen Myelom auf dem International Myeloma Society Annual Meeting am 20. September 2025 vorzustellen. Die Studie, die cemsidomide mit Dexamethason kombiniert, hat Einschluss und Dosiseskalation abgeschlossen.
Die Präsentation wird Daten aller sicherheits- und wirksamkeitsbewerteten Patienten über alle Dosisstufen hinweg enthalten. Erste Ergebnisse zeigen ein gut verträgliches Sicherheitsprofil und überzeugende Ansprechraten. Dr. Binod Dhakal vom Medical College of Wisconsin wird die Ergebnisse um 11:10 Uhr ET in Toronto vorstellen. C4T wird am selben Tag um 15:00 Uhr ET zudem ein Investor-Webcast veranstalten, um die Daten zu besprechen und die zukünftigen klinischen Entwicklungspläne darzulegen.
- None.
- None.
Insights
C4T's Phase 1 cemsidomide trial shows promising safety and efficacy in multiple myeloma, marking significant clinical progress.
C4 Therapeutics' upcoming presentation at the International Myeloma Society Annual Meeting represents a critical milestone in their cemsidomide development program. The press release highlights that the Phase 1 trial has successfully completed enrollment and dose escalation, with early signals of both safety tolerability and efficacy. Their specific mention of "compelling response rates" is particularly noteworthy, as response rates are a key indicator of potential clinical benefit in multiple myeloma trials.
The selection for an oral presentation rather than a poster is significant, as conference organizers typically reserve oral slots for more impactful results. This suggests the data may be more robust than typical early-stage results. The presentation will occur in the "Future Targets and New Modalities of Therapy" session, positioning cemsidomide as a potential novel approach in a field that continues to seek innovative treatments for relapsed/refractory patients.
Cemsidomide represents C4T's MonoDAC® degrader platform technology, which aims to harness targeted protein degradation - an emerging modality with potential advantages over traditional inhibitors. For multiple myeloma specifically, new mechanisms of action are valuable as patients inevitably develop resistance to existing therapies. The Phase 1 results will provide crucial insights into whether this approach could potentially address significant unmet needs in the multiple myeloma treatment landscape.
C4T to Host Webcast on September 20, 2025 at 3 pm ET
WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (IMS) Annual Meeting on September 20, 2025 at 11:10 am ET in Toronto, Canada.
IMS Annual Meeting 2025 Oral Presentation
Title: Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Presentation Date and Time: Saturday, September 20, 2025 at 11:10 am ET
Session: Future Targets and New Modalities of Therapy
Location: Metro Toronto Convention Centre - South Building, Room 701
Presenter: Binod Dhakal, M.D., M.S., associate professor of medicine, Medical College of Wisconsin, Division of Hematology
C4T has completed enrollment and dose escalation for its Phase 1 trial of cemsidomide in MM, which continues to demonstrate a well-tolerated safety profile and compelling response rates. The presentation at the IMS Annual Meeting will include data from all safety and efficacy evaluable MM patients from all dose levels studied in the cemsidomide with dexamethasone cohort in the Phase 1 trial. C4T’s investor webcast will highlight the data from the oral presentation at the IMS Annual Meeting and provide additional detail on the company’s planned next steps of clinical development.
C4T Investor Webcast
C4T will host a webcast on September 20, 2025 at 3 pm ET. To join the webcast, please visit this link or the “Events & Presentations” page of the Investors section on the company’s website at www.c4therapeutics.com. A replay of the webcast will be archived and available following the event. Additionally, following the oral presentation at the IMS Annual Meeting, C4T will share that presentation on its website under the Scientific Presentations and Publications page.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
About Cemsidomide
Cemsidomide is an investigational, orally bioavailable small-molecule degrader designed to be a more potent and selective degrader of IKZF1/3, transcription factors that drive multiple myeloma (MM) and non-Hodgkin’s lymphomas (NHL), with unique pharmacokinetic properties. Clinical data has shown that cemsidomide is well-tolerated. In MM, cemsidomide displays compelling evidence of anti-myeloma activity and immunomodulatory effects. More information may be accessed at www.clinicaltrials.gov (identifier: NCT04756726).
Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
FAQ
When will C4 Therapeutics (CCCC) present cemsidomide Phase 1 data at IMS 2025?
What are the initial results from C4 Therapeutics' (CCCC) cemsidomide Phase 1 trial?
When is C4 Therapeutics' (CCCC) investor webcast for the cemsidomide data?
What will be presented in C4 Therapeutics' (CCCC) IMS presentation?
